Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agape ATP Corporation stock logo
ATPC
Agape ATP
$1.40
+2.6%
$1.70
$0.90
$6.80
$68.01M-0.981.76 million shs44,006 shs
CORBF
Global Cord Blood
$0.55
-62.1%
$1.13
$0.25
$2.00
$66.85M-0.52118,613 shs1,000 shs
OpGen, Inc. stock logo
OPGN
OpGen
$5.02
+6.1%
$4.84
$0.53
$5.25
$50.54M-1.669,289 shs10,479 shs
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$2.42
-2.8%
$2.13
$1.37
$9.13
$93.81M0.99178,977 shs231,461 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agape ATP Corporation stock logo
ATPC
Agape ATP
+4.10%+5.68%-8.82%-9.42%-65.16%
CORBF
Global Cord Blood
-62.07%-63.33%-53.59%-52.17%-50.00%
OpGen, Inc. stock logo
OPGN
OpGen
+6.13%+5.02%+6.81%+39.44%+88.01%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-3.01%-12.64%+56.13%-28.61%-55.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agape ATP Corporation stock logo
ATPC
Agape ATP
N/AN/AN/AN/AN/AN/AN/AN/A
CORBF
Global Cord Blood
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
1.1498 of 5 stars
0.04.00.00.02.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agape ATP Corporation stock logo
ATPC
Agape ATP
0.00
N/AN/AN/A
CORBF
Global Cord Blood
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agape ATP Corporation stock logo
ATPC
Agape ATP
$1.29M53.94N/AN/A$0.48 per share2.91
CORBF
Global Cord Blood
$196.12M0.34$0.39 per share1.40N/A
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M18.91N/AN/A($11.55) per share-0.43
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$80K1,139.52N/AN/A$1.40 per share1.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agape ATP Corporation stock logo
ATPC
Agape ATP
-$2.47M-$0.60N/AN/A-191.34%-30.95%-27.00%8/12/2025 (Estimated)
CORBF
Global Cord Blood
$79.04MN/A0.00N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%N/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$32.90M-$0.94N/AN/AN/A-28,685.22%-51.35%-37.21%8/6/2025 (Estimated)

Latest OPGN, SERA, CORBF, and ATPC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Agape ATP Corporation stock logo
ATPC
Agape ATP
N/A-$0.07N/A-$0.07N/AN/A
5/14/2025Q1 2025
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agape ATP Corporation stock logo
ATPC
Agape ATP
N/AN/AN/AN/AN/A
CORBF
Global Cord Blood
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agape ATP Corporation stock logo
ATPC
Agape ATP
N/A
24.68
24.64
CORBF
Global Cord Blood
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/A
2.02
2.02

Institutional Ownership

CompanyInstitutional Ownership
Agape ATP Corporation stock logo
ATPC
Agape ATP
0.01%
CORBF
Global Cord Blood
N/A
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
54.64%

Insider Ownership

CompanyInsider Ownership
Agape ATP Corporation stock logo
ATPC
Agape ATP
9.67%
CORBF
Global Cord Blood
0.50%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
15.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agape ATP Corporation stock logo
ATPC
Agape ATP
4050.01 million45.17 millionNot Optionable
CORBF
Global Cord Blood
1,200121.55 millionN/ANot Optionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
12037.67 million31.72 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agape ATP stock logo

Agape ATP NASDAQ:ATPC

$1.40 +0.04 (+2.57%)
As of 07/7/2025 03:59 PM Eastern

Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. It offers four series of programs that consist of various services and products under the ATP Zeta Health Program, ÉNERGÉTIQUE, BEAUNIQUE, and E.A.T.S. names. The company's products include ATP1s Survivor Select that contains various essential nutrients required by the human body to maintain normal metabolism; ATP3 Ionized Cal-Mag, a calcium and magnesium minerals supplement; ATP4 Omega Blend, an oil blend that provides a bio-effective balance of essential fatty acids, omega 3, and omega 6; ATP5 BetaMaxx, a natural immune enhancer; AGN-Vege Fruit Fiber, a nutrition-based formulation for intestines and stomach; AGP1-Iron to improve iron deficiency anemia; and YFA-Young Formula, an anti-aging and youthful maintenance supplement. It also provides BEAUNIQUE brand products comprising Mito+, an antioxidant drink for cellular, immune, metabolic, brain, and skin health; and Trim+, which inhibits the activities of carbohydrates digestive enzymes that result in a reduction of the breakdown and absorption of sugars. In addition, the company offers energy masks, including N°1 Med-Hydration, N°2 Med-Whitening, and N°3 Med-Firming, as well as hyaluronic acid serum and mousse facial cleanser under ÉNERGÉTIQUE brand; and soy protein isolate powder, and an antioxidant under Livo5 brand name. Further, it sells health and wellness products; and promotes wellness and wellbeing lifestyle through online editorials, programs, events, and campaigns, as well as provides health therapies. The company was incorporated in 2016 and is headquartered in Kuala Lumpur, Malaysia.

Global Cord Blood NYSE:CORBF

$0.55 -0.90 (-62.07%)
As of 07/7/2025 12:15 PM Eastern

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

OpGen stock logo

OpGen NASDAQ:OPGN

$5.02 +0.29 (+6.13%)
As of 07/7/2025 03:37 PM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Sera Prognostics stock logo

Sera Prognostics NASDAQ:SERA

$2.42 -0.07 (-2.81%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$2.39 -0.03 (-1.24%)
As of 07/7/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.